Procalcitonin for the diagnosis and monitoring of infectious diseases

doi:10.3969/j.issn.1673-8640.2017.03.018

Abstract

Abstract:

Traditional biomarkers,including C-reactive protein（CRP）,leukocyte,erythrocyte sedimentation rate,clinical signs and symptoms,are not sufficiently sensitive or specific enough to guide treatment decisions in infectious diseases. Procalcitonin （PCT） is synthesized by tissues and organs in response to endotoxin or to mediators released,owing to a large number of pathogenic bacterial infection invasion. A growing body of evidence supports the use of PCT as a biomarker to improve the diagnosis of infectious diseases. The monitoring of PCT may contribute to the source control for infections and antibiotic therapy. The review summarizes the clinical application of PCT in different infection diseases.

Key words: Procalcitonin, Infection, Sepsis, Systemic inflammatory response syndrome, Antibiotic guidance

CLC Number:

R446.62

HU Yao. Procalcitonin for the diagnosis and monitoring of infectious diseases[J]. Laboratory Medicine, 2017, 32(3): 234-239.

Figures/Tables 3

References 48

[1]	ASSICOT M,GENDREL D,CARSIN H,et al.High serum procalcitonin concentrations in patients with sepsis and infection[J]. Lancet,1993,341(8844):515-518.
[2]	SCHUETZ P,ALBRICH W,MUELLER B.Procalcitonin for diagnosis of infection and guide to antibiotic decisions:past,present and future[J].BMC Med,2011,9:107.
[3]	GILBERT D N.Use of plasma procalcitonin levels as an adjunct to clinical microbiology[J]. J Clin Microbiol,2010,48(7):2325-2329.
[4]	SEXTON P M,CHRISTOPOULOS G,CHRISTOPOULOS A,et al.Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis[J]. Crit Care Med,2008,36(5):1637-1640.
[5]	LEE H.Procalcitonin as a biomarker of infectious diseases[J]. Korean J Intern Med,2013,28(3): 285-291.
[6]	HOFFMANN G,TOTZKE G,SEIBEL M,et al.In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin[J]. Crit Care Med,2001,29(1): 112-116.
[7]	LINSCHEID P,SEBOEK D,SCHAER D J,et al.Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes[J]. Crit Care Med,2004,32(8):1715-1721.
[8]	GOGOS C A,DROSOU E,BASSARIS H P,et al.Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis:a marker for prognosis and future therapeutic options[J]. J Infect Dis,2000,181(1):176-180.
[9]	LIMPER M,DE KRUIF M D,DUITS A J,et al. The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever[J]. J Infect,2010,60(6):409-416.
[10]	BECKER K L,NYLÉN E S,WHITE J C,et al. Clinical review 167:procalcitonin and the calcitonin gene family of peptides in inflammation,infection,and sepsis:a journey from calcitonin back to its precursors[J]. J Clin Endocrinol Metab,2004,89(4):1512-1525.
[11]	MÜLLER B,BECKER K L,SCHCHINGER H,et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit[J]. Crit Care Med, 2000,28(4):977-983.
[12]	HARBARTH S,HOLECKOVA K,FROIDEVAUX C,et al.Diagnostic value of procalcitonin, interleukin-6,and interleukin-8 in critically ill patients admitted with suspected sepsis[J]. Am J Respir Crit Care Med,2001,164(3):396-402.
[13]	CHARLES P E,DALLE F,AHO S,et al.Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients[J].Intensive Care Med,2006,32(10):1577-1583.
[14]	CHALUPA P,BERAN O,HERWALD H,et al.Evaluation of potential biomarkers for the discrimination of bacterial and viral infections[J].Infection,2011,39(5):411-417.
[15]	CUQUEMELLE E,SOULIS F,VILLERS D,et al.Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study[J]. Intensive Care Med,2011, 37(5):796-800.
[16]	REINHART K,BAUER M,RIEDEMANN N C,et al.New approaches to sepsis:molecular diagnostics and biomarkers[J]. Clin Microbiol Rev, 2012,25(4):609-634.
[17]	SCHUETZ P,ALBRICH W,CHRIST-CRAIN M,et al.Procalcitonin for guidance of antibiotic therapy[J]. Expert Rev Anti Infect Ther,2010,8(5):575-587.
[18]	MANIAN F A.Use of procalcitonin to guide duration of antimicrobial therapy in intensive care units: proceed with caution[J]. Clin Infect Dis,2012,54(4):578.
[19]	TANG B M,ESLICK G D,CRAIG J C,et al.Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis[J]. Lancet Infect Dis,2007,7(3):210-217.
[20]	UZZAN B,COHEN R,NICOLAS P,et al.Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma:a systematic review and meta-analysis[J]. Crit Care Med,2006,34(7):1996-2003.
[21]	TSALIK E L,JAGGERS L B,GLICKMAN S W, et al.Discriminative value of inflammatory biomarkers for suspected sepsis[J]. J Emerg Med,2012,43(1):97-106.
[22]	KOFOED K,ANDERSEN O,KRONBORG G,et al.Use of plasma C-reactive protein, procalcitonin, neutrophils,macrophage migration inhibitory factor,soluble urokinase-type plasminogen activator receptor,and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections:a prospective study[J]. Crit Care,2007,11(2):R38.
[23]	HAEUSLER G M,CARLESSE F,PHILLIPS R S.An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer[J]. Pediatr Infect Dis J,2013,32(10):e390-e396.
[24]	LYU Y X,YU X C,ZHU M Y.Comparison of the diagnostic value of procalcitonin and C-reactive protein after hematopoietic stem cell transplantation: a systematic review and meta-analysis[J]. Transpl Infect Dis,2013,15(3):290-299.
[25]	O'GRADY N P,BARIE P S,BARTLETT J G,et al. Guidelines for evaluation of new fever in critically ill adult patients:2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America[J]. Crit Care Med, 2008,36(4):1330-1349.
[26]	SIMON L,GAUVIN F,AMRE D K,et al.Serum procalcitonin and C-reactive protein levels as markers of bacterial infection:a systematic review and meta-analysis[J]. Clin Infect Dis,2004,39(2):206-217.
[27]	JONES A E,FIECHTL J F,BROWN M D,et al.Procalcitonin test in the diagnosis of bacteremia: a meta-analysis[J]. Ann Emerg Med,2007,50(1):34-41.
[28]	UZZAN B,COHEN R,NICOLAS P,et al.Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma:a systematic review and meta-analysis[J]. Crit Care Med,2006,34(7):1996-2003.
[29]	MOFIDI R,SUTTIE S A,PATIL P V,et al.The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis:systematic review[J]. Surgery, 2009,146(1):72-81.
[30]	VOULOUMANOU E K,PLESSA E,KARAGEORGOPOULOS D E,et al.Serum procalcitonin as a diagnostic marker for neonatal sepsis:a systematic review and meta-analysis[J].Intensive Care Med,2011,37(5):747-762.
[31]	MÜLLER F,CHRIST-CRAIN M,BREGENZER T,et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial[J]. Chest,2010,138(1):121-129.
[32]	VAN NIEUWKOOP C,BONTEN T N,VAN'T WOUT J W,et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome:a prospective observational study[J]. Crit Care,2010,14(6):R206.
[33]	SAKR Y,SPONHOLZ C,TUCHE F,et al.The role of procalcitonin in febrile neutropenic patients: review of the literature[J]. Infection,2008,36(5):396-407.
[34]	LIN S G,HOU T Y,HUANG D H,et al.Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and neutropenia-a systemic review and meta-analysis[J]. Pediatr Infect Dis J,2012,31(10):e182-e188.
[35]	LIN K H,WANG F L,WU M S,et al.Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis[J]. Diagn Microbiol Infect Dis,2014,80(1):72-78.
[36]	HUSOVÁ L,HUSA P,SENKYRIK M,et al.Procalcitonin as an indicator of infection in patients with liver cirrhosis[J]. Vnitr Lek,2004,50(2):153-156.
[37]	ENGLAND J T,DEL VECCHIO M T,ARONOFF S C. Use of serum procalcitonin in evaluation of febrile infants:a meta-analysis of 2 317 patients[J]. J Emerg Med,2014,47(6):682-688.
[38]	MARIN REINA P,RUIZ ALCÁNTARA I,VIDAL MICÓ S,et al. Accuracy of the procalcitonin test in the diagnosis of occult bacteremia in paediatrics:a systematic review and meta-analysis[J]. An Pediatr (Barc),2010,72(6):403-412.
[39]	RADIMERSKI T M,GRISOUARD J,TIMPER K,et al.Role of calcium in lipopolysaccharide-induced calcitonin gene expression in human adipocytes[J].Innate Immun,2011,17(4):403-413.
[40]	DE KRUIF M D,LEMAIRE L C,GIEBELEN I A,et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia[J]. Intensive Care Med,2008,34(3):518-522.
[41]	REINHART K,MEISNER M.Biomarkers in the critically ill patient:procalcitonin[J]. Crit Care Clin,2011,27(2):253-263.
[42]	DELLINGER R P,LEVY M M,CARLET J M,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock:2008[J]. Intensive Care Med,2008,34(1):17-60.
[43]	SCHUETZ P,CHIAPPA V,BRIEL M,et al.Procalcitonin algorithms for antibiotic therapy decisions:a systematic review of randomized controlled trials and recommendations for clinical algorithms[J]. Arch Intern Med,2011,171(15): 1322-1331.
[44]	KOPTERIDES P,SIEMPOS I I,TSANGARIS I,et al.Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit:a systematic review and meta-analysis of randomized controlled trials[J].Crit Care Med,2010,38(11):2229-2241.
[45]	SCHUETZ P,MÜLLER B,CHRIST-CRAIN M,et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections[J]. Evid Based Child Health,2013,8(4):1297-1371.
[46]	BECKER K L,SNIDER R,NYLEN E S.Procalcitonin assay in systemic inflammation, infection,and sepsis:clinical utility and limitations[J]. Crit Care Med,2008,36(3):941-952.
[47]	AABENHUS R,JENSEN JU.Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting:are we there yet?[J]. Prim Care Respir J,2011,20(4):360-367.
[48]	冯仁丰. 降钙素原的标准化[J]. 临床实验室, 2014,8(10):46-47.

参考文献	感染标志物	特异性（%）	敏感性（%）	阈值
急诊疑似脓毒症患者PCT、CRP和IL-6水平与感染或败血症的相关性^[21]	PCT	感染：63~97	感染：68~18	0.1~3.0 ng/mL
急诊疑似脓毒症患者PCT、CRP和IL-6水平与感染或败血症的相关性^[21]	PCT	败血症：38~90	败血症：91~47	0.1~3.0 ng/mL
	IL-6	感染：67~96	感染：58~14	40~500 pg/mL
	IL-6	败血症：34~89	败血症：90~27	40~500 pg/mL
	CRP	感染：33~88	感染：90~43	40~100 mg/dL
	CRP	败血症：39~88	败血症：82~31	40~100 mg/dL
78例重症疑似感染和SIRS患者PCT和IL-6水平与脓毒症的相关性^[13]	PCT	78	97	1.1 ng/mL
78例重症疑似感染和SIRS患者PCT和IL-6水平与脓毒症的相关性^[13]	IL-6	72	67	200 pg/mL
急诊及感染科诊治161例社区获得性感染患者的队列研究^[22]	PCT	58	80	0.28 ng/mL
急诊及感染科诊治161例社区获得性感染患者的队列研究^[22]	白细胞计数	74	64	8.5×10⁹/L

参考文献	感染标志物	特异性（%）	敏感性（%）	阈值
急诊疑似脓毒症患者PCT、CRP和IL-6水平与感染或败血症的相关性^[21]	PCT	感染：63~97	感染：68~18	0.1~3.0 ng/mL
急诊疑似脓毒症患者PCT、CRP和IL-6水平与感染或败血症的相关性^[21]	PCT	败血症：38~90	败血症：91~47	0.1~3.0 ng/mL
	IL-6	感染：67~96	感染：58~14	40~500 pg/mL
	IL-6	败血症：34~89	败血症：90~27	40~500 pg/mL
	CRP	感染：33~88	感染：90~43	40~100 mg/dL
	CRP	败血症：39~88	败血症：82~31	40~100 mg/dL
78例重症疑似感染和SIRS患者PCT和IL-6水平与脓毒症的相关性^[13]	PCT	78	97	1.1 ng/mL
78例重症疑似感染和SIRS患者PCT和IL-6水平与脓毒症的相关性^[13]	IL-6	72	67	200 pg/mL
急诊及感染科诊治161例社区获得性感染患者的队列研究^[22]	PCT	58	80	0.28 ng/mL
急诊及感染科诊治161例社区获得性感染患者的队列研究^[22]	白细胞计数	74	64	8.5×10⁹/L

参考文献	特异性（%）	敏感性（%）	阈值（ng/mL）	临床相关性
住院患者（46例新生儿、638例儿童和702例成年人）PCT和CRP对诊断细菌感染准确性的研究^[26]	83	85	0.5~6.1	PCT诊断准确性优于 CRP
PCT对2 008例急诊患者菌血症诊断准确性的研究^[27]	70	76	0.4~0.5	PCT对急诊菌血症诊断性能一般
PCT对3 943例危重成人患者、外伤或手术患者诊断脓毒症、严重脓毒症或感染性休克准确性的研究^[28]	48~100	100~42	0.6~5.0	PCT是良好的生物学诊断标志物且优于CRP
PCT作为重症急性胰腺炎及感染坏死性胰腺炎诊断标志物的研究^[29]	重症急性胰腺炎：86 感染坏死性胰腺炎：91	重症急性胰腺炎：72 感染坏死性胰腺炎：80	>0.5	PCT可预测急性胰腺炎的严重程度和预估发生感染性胰腺坏死的风险
PCT对1 959例新生儿的脓毒症诊断准确性的研究^[30]	79	81	> 0.25	PCT对新生儿脓毒症的诊断具有良好的准确性

参考文献	特异性（%）	敏感性（%）	阈值（ng/mL）	临床相关性
住院患者（46例新生儿、638例儿童和702例成年人）PCT和CRP对诊断细菌感染准确性的研究^[26]	83	85	0.5~6.1	PCT诊断准确性优于 CRP
PCT对2 008例急诊患者菌血症诊断准确性的研究^[27]	70	76	0.4~0.5	PCT对急诊菌血症诊断性能一般
PCT对3 943例危重成人患者、外伤或手术患者诊断脓毒症、严重脓毒症或感染性休克准确性的研究^[28]	48~100	100~42	0.6~5.0	PCT是良好的生物学诊断标志物且优于CRP
PCT作为重症急性胰腺炎及感染坏死性胰腺炎诊断标志物的研究^[29]	重症急性胰腺炎：86 感染坏死性胰腺炎：91	重症急性胰腺炎：72 感染坏死性胰腺炎：80	>0.5	PCT可预测急性胰腺炎的严重程度和预估发生感染性胰腺坏死的风险
PCT对1 959例新生儿的脓毒症诊断准确性的研究^[30]	79	81	> 0.25	PCT对新生儿脓毒症的诊断具有良好的准确性

PCT阈值（ng/mL）	临床诊断	抗菌药物管理
< 0.1	非细菌性感染	不使用抗菌药物,6~24 h内复测PCT水平,根据临床症状与复检结果再进行评估
0.1~0.25	细菌性感染可能性小	不使用抗菌药物,但出现下列情况时,考虑使用抗菌药物：（1）生命体征异常;（2）需要重症监护;（3）肺气肿;（4）细菌培养阳性
> 0.25~0.5	可能细菌感染	使用抗菌药物,并于用药后第3、5、7天复查PCT
> 0.5	细菌感染可能性大	使用抗菌药物,治疗第3、5、7天复查PCT,若PCT水平下降80%~90%, 则考虑停止使用抗菌药物;若PCT水平持续升高,则表明治疗失败